• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Alkermes plc

    7/29/25 4:09:29 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    S-8 1 alks-20250729.htm S-8 S-8

    As filed with the Securities and Exchange Commission on July 29, 2025

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     

    ALKERMES PUBLIC LIMITED COMPANY

    (Exact name of registrant as specified in its charter)

     

    Ireland

    98-1007018

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    Connaught House

    1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Address of Principal Executive Offices)

     

     

    ALKERMES PLC 2018 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED

    (Full title of the plan)

     

    David J. Gaffin, Esq.

    Alkermes plc

    Connaught House

    1 Burlington Road

    Dublin 4, Ireland D04 C5Y6

    (Name and address of agent for service)

     

    Telephone: +353-1-772-8000

    (Telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

     

    Mitchell S. Bloom, Esq.

    Robert E. Puopolo, Esq.

    Stephanie Richards, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    Telephone: 617-570-1000

     

    and

     

    Christopher McLaughlin

    Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland

    Telephone: +353 1 920 1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

    Large accelerated filer 

     

    Accelerated filer 

    Non-accelerated filer 

     

    Smaller reporting company 

    Emerging growth company 

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     


     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (this “Registration Statement”) is being filed for the purpose of registering an additional 4,250,000 ordinary shares, par value $0.01 per share, of the Registrant (“Shares”) that may be issued pursuant to the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. The securities subject to this Registration Statement are of the same class of securities of the Registrant for which the Registrant previously filed registration statements on Form S-8 on February 16, 2012 (File No. 333-179545), October 26, 2012 (File No. 333-184621), December 5, 2014 (File No. 333-200777), December 7, 2016 (File No. 333-214952) and July 26, 2018 (File No. 333-226359), each amended by Post-Effective Amendment No. 1 filed by the Registrant on July 29, 2020, and registration statements on Form S-8 on July 25, 2019 (File No. 333-232831), July 29, 2020 (File No. 333-240170), July 28, 2021 (File No. 333-258229), July 27, 2022 (File No. 333-266350), July 26, 2023 (File No. 333-273456) and July 24, 2024 (File No. 333-280984) (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements, as filed with the United States Securities and Exchange Commission (the “Commission”), are hereby incorporated by reference pursuant to General Instruction E to Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents are hereby incorporated by reference into this Registration Statement (other than those portions of such documents that are furnished or otherwise not deemed to be filed):

     

    (i) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024;

     

    (ii) The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025;

     

    (iii) The Registrant’s Current Reports on Form 8-K filed with the Commission on April 16, 2025 and May 21, 2025 (excluding any portions of such Current Reports on Form 8-K that were furnished under Item 2.02 or Item 7.01 of Form 8-K and any exhibits related thereto); and

     

    (iv) The description of the Shares contained in the “Description of Securities” filed as Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, including any amendment or report filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing such documents. Any statement contained herein or in a document incorporated by reference or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that such statement is modified or superseded by any other subsequently filed document which is incorporated or is deemed to be incorporated by reference herein. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

    The Irish Companies Act 2014 permits a company to pay the costs or discharge the liability of a director or a secretary only where favorable judgment is given in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or secretary acted honestly and reasonably and ought fairly to be excused. This restriction does not apply to executives who are not directors or a secretary of the Registrant. Any provision by an Irish company which seeks to indemnify a

     


     

    director or secretary of that Irish company over and above this shall be void under Irish law, whether contained in such company’s articles of association or any contract between the director or secretary and such company.

    Pursuant to the Registrant’s articles of association, the Registrant will indemnify its current and former executives, any person who is serving or has served at the request of the Registrant as a director, executive or trustee of another company, joint venture, trust or other enterprise, and its directors and secretaries to the fullest extent permitted by law, against liabilities that are incurred by such executives, trustees, directors and secretaries while executing the duties of their respective offices. However, under the articles of association of the Registrant, unless the adjudicating court determines otherwise, such executives, trustees, directors and secretaries will not be entitled to indemnification by the Registrant if they are adjudged to be liable for fraud or dishonesty in the performance of their duties to the Registrant.

    The current and certain former directors, secretaries and executive officers of the Registrant, and certain directors and officers of certain of the Registrant’s subsidiaries, including Alkermes, Inc., are entitled to be indemnified pursuant to indemnification agreements with the Registrant and/or Alkermes, Inc. Under the terms of these indemnification agreements, and subject to any conditions to indemnity set forth therein, (i) the Registrant and/or Alkermes, Inc., as applicable, indemnifies each relevant director, secretary, or officer to the maximum extent permitted by law for expenses and other amounts actually and reasonably incurred by or on behalf of the director, secretary, or officer in relation to claims brought against such director, secretary, or officer that arise from actions taken while acting as a director, secretary, or officer of the Registrant and/or its subsidiaries, except to the extent that such indemnification is prohibited by applicable law or would be duplicative of amounts otherwise actually provided to such director, secretary, or officer in relation to such claims; (ii) the Registrant and/or Alkermes, Inc. will, to the maximum extent permitted by law, advance the expenses of such director, secretary, or officer in connection with his or her defense and (iii) each director, secretary, or officer undertakes, to the fullest extent required by law, to repay all amounts advanced if and to the extent it is ultimately determined by a court of competent jurisdiction in a final judgment that he or she is not entitled to be indemnified by the Registrant and/or Alkermes, Inc., as applicable.

    The Registrant has also obtained directors’ and officers’ liability insurance which insures its executives and directors against certain liabilities that such persons may incur in their capacities as officers and/or directors of the Registrant.

     

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following exhibits are filed as part of this Registration Statement:

     

     

     

    Exhibit No.

     

    Description of Exhibit

    4.1

     

    Memorandum and Articles of Association of Alkermes plc (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 1, 2024 (File No. 001-35299)).

     

     

     

    4.2

     

    Alkermes plc 2018 Stock Option and Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on May 21, 2025 (File No. 001-35299)).

     

     

     

    5.1*

     

    Opinion of Arthur Cox LLP, Solicitors, as to the legality of the securities being registered.

     

     

     

    23.1*

     

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

     

     

     

    23.2*

     

    Consent of Arthur Cox LLP, Solicitors (included in Exhibit 5.1 filed herewith).

     

     

     

    24*

     

    Power of Attorney (included in signature page).

     

     

     

    107*

     

    Filing Fee Table.

     

     

     

    * Filed herewith.

     

     


     

     

    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

     

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(l)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

    (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

    [THE NEXT PAGE IS THE SIGNATURE PAGE]

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Clarinbridge, Ireland, on July 29, 2025.

    ALKERMES PLC

    By:

    /s/ Tom Riordan

    Name:

    Tom Riordan

    Title:

    Assistant Company Secretary

     

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers, directors and/or authorized representative in the United States of the Registrant hereby severally constitute and appoint Richard F. Pops and Blair C. Jackson, and each of them, our true and lawful attorney-in-fact, with full power of substitution, to sign for us and in our names and the capacities indicated below, to execute and cause to be filed with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, with exhibits thereto and all other documents in connection therewith, and generally to do or cause to be done by virtue hereof all things in our names and on our behalf in such capacities to enable the Registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    SIGNATURE

    TITLE

    DATE

     

    /s/ Richard F. Pops

    Chairman and Chief Executive Officer

    July 29, 2025

    Richard F. Pops

    (Principal Executive Officer and Authorized Representative in the U.S.)

     

    /s/ Blair C. Jackson

    Executive Vice President, Chief Operating Officer

    (Interim Principal Financial Officer)

    July 29, 2025

    Blair C. Jackson

     

    /s/ Samuel J. Parisi

     

    Vice President, Finance

    (Interim Principal Accounting Officer)

     

    July 29, 2025

    Samuel J. Parisi

     

     

     

     

     

     

     

     

     

    /s/ Shane M. Cooke

     

    Director

     

    July 29, 2025

    Shane M. Cooke

     

     

     

     

     

    /s/ Richard B. Gaynor

    Director

    July 29, 2025

    Richard B. Gaynor

     

     

     

     

     

    /s/ Cato T. Laurencin

    Director

    July 29, 2025

    Cato T. Laurencin

     

    /s/ Nancy S. Lurker

     

    Director

     

    July 29, 2025

    Nancy S. Lurker

     

     

     

     

     

     

     

     

     

    /s/ Brian P. McKeon

    Director

    July 29, 2025

    Brian P. McKeon

     

    /s/ Nancy L. Snyderman

    Director

    July 29, 2025

    Nancy L. Snyderman

     

    /s/ Frank Anders Wilson

    Director

    July 29, 2025

    Frank Anders Wilson

     

     

     

     

     

    /s/ Christopher I. Wright

    Director

    July 29, 2025

    Christopher I. Wright

     

     


    Get the next $ALKS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    11/11/2025$50.00Buy
    Truist
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

    Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patients with NT1. Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). The FDA's Breakthrough Therapy designation process is designed to expedite the development and review of drugs that are intended to treat

    1/6/26 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dep

    12/30/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Announcement relating to despatch of Rule 15 proposal

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorporated in Ireland (the "Company" or "Avadel") and the board of directors of Alkermes plc (NASDAQ:ALKS), a public limited company incorporated in Ireland ("Alkermes") reached agreement on the ter

    12/5/25 4:01:00 PM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Alkermes Plc with a new price target

    Truist initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $50.00

    11/11/25 8:03:02 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Alkermes Plc with a new price target

    Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00

    9/3/25 8:26:50 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    1/12/26 8:00:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    1/6/26 7:06:35 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Alkermes plc

    144 - Alkermes plc. (0001520262) (Subject)

    12/1/25 4:45:22 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director and CEO, Alkermes plc Pops Richard F was granted 149,580 units of Ordinary Shares and covered exercise/tax liability with 62,230 units of Ordinary Shares, increasing direct ownership by 7% to 1,377,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:14:03 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Commercial Officer Nichols Christian Todd was granted 21,127 units of Ordinary Shares and covered exercise/tax liability with 6,389 units of Ordinary Shares, increasing direct ownership by 17% to 100,946 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:13:20 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Operating Officer Jackson Blair Curtis was granted 28,810 units of Ordinary Shares and covered exercise/tax liability with 8,626 units of Ordinary Shares, increasing direct ownership by 10% to 221,552 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    2/6/26 7:12:38 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (NASDAQ:AVDL) ("Avadel") today announced that the companies have reached agreement on the terms of an increased recommended offer under which Alkermes will acquire Avadel (the "Acquisition") for total transaction consideration of up to $22.50 per share, consisting of $21.00 in cash and one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional ca

    11/19/25 6:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2

    – Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the Study's Dual Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Patients With Narcolepsy Type 2 – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast on Wednesday, Nov. 12 at 8:30 a.m. ET – DUBLIN, Nov. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phas

    11/12/25 7:30:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports Third Quarter 2025 Financial Results

    —    Third Quarter Revenues of $394.2 Million — —    GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —    Company Raises 2025 Financial Expectations — DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals annou

    10/28/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care